Status:
RECRUITING
Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer
Lead Sponsor:
Minia University
Conditions:
Surgery
Neoadjuvant Chemotherapy
Eligibility:
All Genders
18+ years
Brief Summary
This trial aimed to determine whether neoadjuvant chemoradiotherapy improves overall survival compared with upfront surgery, both followed by adjuvant chemotherapy in patients with resectable and bord...
Detailed Description
Pancreatic cancer is one of the solid cancers with the poorest treatment outcomes, and there is an urgent need to improve its treatment outcomes. Among these, resectable pancreatic cancer is known to ...
Eligibility Criteria
Inclusion
- Computed tomography (CT) with pancreatic protocol + vascular mapping
- Histopathologically proven malignant by CT-guided or endoscopic ultrasound (EUS)-guided biopsy Resectable pancreatic cancer means no contact of the tumor with the Superior mesenteric artery, Celiac axis \& Common hepatic artery, and contact of the tumor but ≤90° contact with the superior mesenteric vein \& portal vein.
Exclusion
- Borderline resectable \& locally advanced pancreatic cancer
- Tumor at the tail of the pancreas.
- Metastatic pancreatic cancer
- Unfit patients for surgery.
Key Trial Info
Start Date :
February 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06978322
Start Date
February 1 2025
End Date
February 1 2026
Last Update
May 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Minia University
Minya, Egypt, 61611